Citation

Giner L, Nichols CM, Zalsman G, Oquendo MA. Int. J. Adolesc. Med. Health 2005; 17(3): 211-220.

Affiliation

Puerta de Hierro Hospital, Universidad Autonoma de Madrid, Madrid, Spain. lginer@neuron.cpmc.columbia.edu

Copyright

(Copyright © 2005, Freund Publishing)

DOI

unavailable

PMID

16231472

Abstract

The controversy regarding Selective Serotonin Reuptake Inhibitors (SSRIs) and suicidality dates back to the early 1990s. The first agent reported to be associated with suicidality was fluoxotine. In 2003, the British Medicines and Healthcare Products Regulatory Agency (MHRA) warned about possible risk of suicidality in children and adolescents treated with paroxetine for Major Depressive Disorder (MDD). This warning was soon extended to all the SSRIs as well as venlafaxine and mirtazapine. Similarly, the United States Food and Drug Administration (FDA) issued a "black box warning" on these medications in 2004. We address the debate concerning this warning and its clinical implications and review the latest contributions to the literature.

Language: en